Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City

COVID Clinical Trial

— COVIDGHPSJCite  

Official title:

Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04365530
• Other study ID #: Cohorte COVID GHPSJ CiteH
• Status: Completed
• Start date: April 1, 2020
• Est. completion date: March 6, 2023

Study information

• Verified date: March 2023
• Source: Groupe Hospitalier Paris Saint Joseph
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The ongoing Coronavirus (Covid-19) pandemic is causing a major global health crisis and is shaking up hospital organizations. To date, the recognized risk factors for severe forms of Covid-19 infection are elderly patients (> 70 years), obese patients, patients with chronic renal or respiratory pathologies, cardiovascular history (stroke or coronary artery disease), chronic respiratory conditions, high blood pressure, diabetes, and cancer. Covid-19 is manifested by a risk of acute respiratory distress syndrome requiring management by invasive ventilation. The lethality of this infection is around 4% in the current data.

Drastic precautionary measures for the transmission of the virus, as well as the provision of critical care beds by canceling any scheduled non-urgent intervention or consultation, have shaken up the hospital organization.

In this context, it is essential to have forward-looking data in real time to adjust the care offer and better understand the impact of Covid-19 on the patient populations treated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3767
• Est. completion date: March 6, 2023
• Est. primary completion date: June 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patient (of all ages) with symptoms compatible with infection by Covid-19 treated at the GHPSJ or in one of the establishments in the Paris Plaisance hospital city.

Exclusion Criteria:

• Asymptomatic patient

• Patient objecting to the use of their data

Related Conditions & MeSH terms

• COVID

Locations

Country	Name	City	State
France	Hôpital Marie Lannelongue	Le Plessis-Robinson
France	AURA Paris Plaisance	Paris
France	Fondation Sainte-Marie	Paris
France	Groupe Hospitalier Paris Saint-Joseph	Paris
France	Hôpital Bellan	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Groupe Hospitalier Paris Saint Joseph

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical consequences of a Covid-19 infection in the care population	This outcome measures the clinical consequences of a Covid-19 infection in the care population.	Year 2
Secondary	Risk factors at M6	This outcome evaluates the risk factors of COVID-19 at month 6	Month 6
Secondary	Risk factors at year 1	This outcome evaluates the risk factors of COVID-19.	Year 1
Secondary	Risk factors at year 2	This outcome evaluates the risk factors of COVID-19.	Year 2
Secondary	Impact of hospital reorganization on medical care at M6	This outcome evaluates the impact of hospital reorganization on medical care at month 6.	Month 6
Secondary	Impact of hospital reorganization on medical care at Year 1	This outcome evaluates the impact of hospital reorganization on medical care at year 1.	Year 1
Secondary	Impact of hospital reorganization on medical care at Year 2	This outcome evaluates the impact of hospital reorganization on medical care at year 2.	Year 2